MedWatch

Analyst: William Demant is under pressure

With a modest sales growth and expectations of no-growth on the bottom line, today’s quarterly financial statement from William Demant reveals a company under immense pressure, according to analyst Morten Imgaard – and there are no signs of a turn-around in Q4.

Foto: William Demant

“I dwell on the fact that Q3-growth does not exceed the average market growth, but is even somewhat less than the market development, and to me that’s evidence of the pressure William Demant is under to update their product portfolio – especially for the high-price segment.”

Sydbank’s stock market analyst Morten Imgaard is less than impressed with the financial statement from the Danish hearing devices manufacturer William Demant, which reveals a modest top line growth, and an even more modest bottom line growth. The company simply needs new high-priced products, he believes.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier